Singapore markets close in 49 minutes
  • Straits Times Index

    3,168.99
    -12.98 (-0.41%)
     
  • Nikkei

    26,571.87
    +140.32 (+0.53%)
     
  • Hang Seng

    17,873.00
    +17.86 (+0.10%)
     
  • FTSE 100

    7,059.43
    +38.48 (+0.55%)
     
  • BTC-USD

    20,199.62
    +1,239.89 (+6.54%)
     
  • CMC Crypto 200

    461.33
    +28.23 (+6.52%)
     
  • S&P 500

    3,655.04
    -38.19 (-1.03%)
     
  • Dow

    29,260.81
    -329.60 (-1.11%)
     
  • Nasdaq

    10,802.92
    -65.00 (-0.60%)
     
  • Gold

    1,644.40
    +11.00 (+0.67%)
     
  • Crude Oil

    77.70
    +0.99 (+1.29%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,412.96
    -0.08 (-0.01%)
     
  • Jakarta Composite Index

    7,125.92
    -1.59 (-0.02%)
     
  • PSE Index

    6,020.07
    -239.47 (-3.83%)
     

scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

·1-min read

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

Event:

H.C. Wainwright 23rd Annual Global Investment Conference
Monday, September 13 – Wednesday, September 15
A webcast of Mr. Tucker’s presentation will be available on-demand as of 7am EDT, Monday, September 13. It can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com

Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com